Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2002-05-18

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0111346PMID 12061878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.

  2001cited by this paper
• Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors.

  2001cited by this paper
• Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.

  2001cited by this paper
• Perspectives on factor Xa inhibition.

  2001cited by this paper
• Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.

  2000cited by this paper
• Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.

  2000cited by this paper
• 1,2-Dibenzamidobenzene inhibitors of human factor Xa.

  2000cited by this paper
• Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.

  2000cited by this paper
• Identification of a binding site for quaternary amines in factor Xa.

  2000cited by this paper
• Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.

  2000cited by this paper
• GRID/CPCA: a new computational tool to design selective ligands.

  2000cited by this paper
• Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: structures based on the (D)-Arg-Gly-Arg tripeptide sequence.

  2000cited by this paper
• Crystal structures of human factor Xa complexed with potent inhibitors.

  2000cited by this paper
• Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.

  2000cited by this paper
• N(2)-Aroylanthranilamide inhibitors of human factor Xa.

  2000cited by this paper
• Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.

  1999cited by this paper
• Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.

  1999cited by this paper
• Molecular structures and conformations of three 3-azabicyclononanes.

  1999cited by this paper
• Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding.

  1999cited by this paper
• Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.

  1999cited by this paper
• Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries

  1999cited by this paper
• Cation-pi interactions in structural biology.

  1999cited by this paper
• Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.

  1999cited by this paper
• Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.

  1999cited by this paper
• Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.

  1999cited by this paper
• Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.

  1999cited by this paper
• Structural basis for chemical inhibition of human blood coagulation factor Xa.

  1998cited by this paper
• Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.

  1998cited by this paper
• Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.

  1998cited by this paper
• Random or rational design? Evaluation of diverse compound subsets from chemical structure databases.

  1998cited by this paper
• Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa.

  1998cited by this paper
• Tetrahydro-isoquinoline-based factor Xa inhibitors.

  1998cited by this paper
• Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation

  1997cited by this paper
• QXP: Powerful, rapid computer algorithms for structure-based drug design

  1997cited by this paper
• A fast flexible docking method using an incremental construction algorithm.

  1996cited by this paper
• Potential advantages of direct‐acting thrombin inhibitors

  1996cited by this paper
• Cation-π Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, and Trp

  1996cited by this paper
• X-ray Structure of Active Site-inhibited Clotting Factor Xa

  1996cited by this paper
• DX-9065a, an Orally Active, Specific Inhibitor of Factor Xa, Inhibits Thrombosis without Affecting Bleeding Time in Rats

  1995cited by this paper
• 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors.

  1995cited by this paper
• Planar stacking interactions of arginine and aromatic side-chains in proteins.

  1994cited by this paper
• Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

  1994cited by this paper
• Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

  1994cited by this paper
• Extending the trend vector: The trend matrix and sample-based partial least squares

  1994cited by this paper
• Structure of human des(1-45) factor Xa at 2.2 A resolution.

  1993cited by this paper
• Components and Assembly of the Factor X Activating Complex

  1992cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

  1990cited by this paper
• Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa.

  1990cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.

  1985cited by this paper
• [Synthesis of N-alpha-(arylsulfonylglycyl)amidinophenylalanine amides as highly active inhibitors of thrombin].

  1984cited by this paper
• The Protein Data Bank: a computer-based archival file for macromolecular structures.

  1977cited by this paper

• Interpretable machine learning-driven QSAR modeling for coagulation factor X inhibitors: from molecular descriptors to predictive potency

  2026cites this paper
• Impact of Varying Velocities and Solvation Boxes on Alchemical Free-Energy Simulations

  2025cites this paper
• Leveraging a Separation of States Method for Relative Binding Free Energy Calculations in Systems with Trapped Waters

  2024cites this paper
• A comparison between 2D and 3D descriptors in QSAR modeling based on bio‐active conformations

  2023cites this paper
• Cribado virtual y análisis de complejos enzima-ligando para el factor Xa (FXa) en la cascada de la coagulación humana

  2023cites this paper
• Dose–Response Activity-Based DNA-Encoded Library Screening

  2023cites this paper
• Deep Batch Active Learning for Drug Discovery

  2023cites this paper
• Probing Factor Xa Protein-Ligand Interactions: Accurate Free Energy Calculations and Experimental Validations of Two Series of High-Affinity Ligands.

  2022cites this paper
• Interpretation of Structure-Activity Relationships in Real-World Drug Design Data Sets Using Explainable Artificial Intelligence

  2022cites this paper
• Structural Characterization of Haemophilus influenzae Enolase and Its Interaction with Human Plasminogen by In Silico and In Vitro Assays

  2021influential citation
• Application of Deep Neural Network Models in Drug Discovery Programs

  2021cites this paper
• Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure.

  2021cites this paper
• Automated De-Novo Design in Medicinal Chemistry: Which Types of Chemistry Does a Generative Neural Network Learn?

  2020cites this paper
• 2-Aminobenzamide-Based Factor Xa Inhibitors with Novel Mono- and Bi-Aryls as S4 Binding Elements

  2019cites this paper
• Design and synthesis of novel 3,4-diaminobenzoyl derivatives as antithrombotic agents with improved solubility

  2018cites this paper
• Mining of Interaction Geometries in Collections of Protein Structures

  2018cites this paper
• A Simple and Direct Synthesis of Pentasubstituted Pyrroles via [3+4] Annulation and Their In Vitro Evaluation as Thrombolytic Agents and Cytotoxicity Studies on L929 Cells

  2018cites this paper
• Can MM/GBSA calculations be sped up by system truncation?

  2018cites this paper
• Thermodynamic Characterization of Hydration Sites from Integral Equation-Derived Free Energy Densities: Application to Protein Binding Sites and Ligand Series

  2017cites this paper
• Can System Truncation Speed up Ligand-Binding Calculations with Periodic Free-Energy Simulations?

  2017influential citation
• Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases.

  2016cites this paper
• Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation

  2016cites this paper
• Open Peer Review

  2016cites this paper
• I2–DMSO promoted metal free oxidative cyclization for the synthesis of substituted Indoles and pyrroles

  2016cites this paper
• Synthesis of spiro isoindolinone-indolines and 1,2-disubstituted indoles from 2-iodobenzamide derivatives

  2016cites this paper
• Application of Molecular Modeling to Development of New Factor Xa Inhibitors

  2015cites this paper
• Strong Nonadditivity as a Key Structure–Activity Relationship Feature: Distinguishing Structural Changes from Assay Artifacts

  2015cites this paper
• Computer-aided drug discovery

  2015cites this paper
• Exploring conformational search protocols for ligand-based virtual screening and 3-D QSAR modeling

  2015cites this paper
• Prediction of thrombin and factor xa inhibitory activity with associative neural networks.

  2015cites this paper
• Towards an automated computational pipeline to guide drug lead optimization

  2015cites this paper
• Thermodynamics of Water in an Enzyme Active Site: Grid-Based Hydration Analysis of Coagulation Factor Xa

  2014cites this paper
• A Large-Scale Test of Free-Energy Simulation Estimates of Protein-Ligand Binding Affinities

  2014cites this paper
• Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling

  2014influential citation
• One-pot approach to 1,2-disubstituted indoles via Cu(II)-catalyzed coupling/cyclization under aerobic conditions and its application for the synthesis of polycyclic indoles.

  2014cites this paper
• Inclusion of Multiple Fragment Types in the Site Identification by Ligand Competitive Saturation (SILCS) Approach

  2013cites this paper
• Lead optimization mapper: automating free energy calculations for lead optimization

  2013cites this paper
• Structural role of exon-coded fragment of polypeptide chains in selected enzymes.

  2013cites this paper
• 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.

  2013cites this paper
• Comparison of end‐point continuum‐solvation methods for the calculation of protein–ligand binding free energies

  2012cites this paper
• The role of structural information in the discovery of direct thrombin and factor Xa inhibitors.

  2012cites this paper
• Improving the Efficiency of Protein-Ligand Binding Free-Energy Calculations by System Truncation.

  2012cites this paper
• The Normal-Mode Entropy in the MM/GBSA Method: Effect of System Truncation, Buffer Region, and Dielectric Constant

  2012cites this paper
• Studies based on supramolecular chemistry in drug design and improvement of pharmaceutical solids

  2012cites this paper
• Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.

  2012cites this paper
• Designing direct and indirect factor Xa inhibitors

  2012cites this paper
• Pharmacophore Modeling and Docking Based QSAR Studies of Aryl Amidino Isoxazoline Derivatives to Design Potential FXa Inhibitors

  2012cites this paper
• Halogen…π Interactions as Important Contributors to Binding Affinity in Medicinal Chemistry

  2012cites this paper
• Protein Pharmacophore Selection Using Hydration-Site Analysis

  2012cites this paper
• Application of Drug-Perturbed Essential Dynamics/Molecular Dynamics (ED/MD) to Virtual Screening and Rational Drug Design.

  2012cites this paper
• A semiempirical approach to ligand‐binding affinities: Dependence on the Hamiltonian and corrections

  2012cites this paper
• Binding affinities in the SAMPL3 trypsin and host–guest blind tests estimated with the MM/PBSA and LIE methods

  2012cites this paper
• A comparison of different initialization protocols to obtain statistically independent molecular dynamics simulations

  2011cites this paper
• Accurate predictions of nonpolar solvation free energies require explicit consideration of binding-site hydration.

  2011cites this paper
• Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches

  2011cites this paper
• Binding Affinities of Factor Xa Inhibitors Estimated by Thermodynamic Integration and MM/GBSA

  2011cites this paper
• 3D-QSAR - APPLICATIONS, RECENT ADVANCES, AND LIMITATIONS

  2010cites this paper
• Update 1 of: Beta-strand mimetics.

  2010cites this paper
• How accurate are continuum solvation models for drug-like molecules?

  2009cites this paper
• Substituent diversity-directed synthesis of indole derivatives.

  2009cites this paper
• An improved method to predict the entropy term with the MM/PBSA approach

  2009cites this paper
• Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites.

  2008cites this paper
• Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering.

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 82 Structure-Based Virtual Screening New Methods and Applications in Infectious Diseases

  2008cites this paper
• Structure-Based Virtual Screening : New Methods and Applications in Infectious Diseases

  2008cites this paper
• Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.

  2008cites this paper
• Diverse, high-quality test set for the validation of protein-ligand docking performance.

  2007cites this paper
• Prediction of factor Xa inhibitors by machine learning methods.

  2007cites this paper
• MED-SuMoLig: A New Ligand-Based Screening Tool for Efficient Scaffold Hopping

  2007cites this paper
• Classification of water molecules in protein binding sites.

  2007cites this paper
• Probing the potential energy landscape for dissociation of protonated indole via threshold collision-induced dissociation and theoretical studies

  2007cites this paper
• An iterative knowledge‐based scoring function to predict protein–ligand interactions: II. Validation of the scoring function

  2006cites this paper
• Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

  2006cites this paper
• Ligand Bias of Scoring Functions in Structure-Based Virtual Screening

  2006cites this paper
• Optimized Modified Topliss Method: A Tool for Quantitative Structure-Activity Relationship Studies

  2005cites this paper
• Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand.

  2005cites this paper
• Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions.

  2005cites this paper
• Reengineering the pharmaceutical industry by crash-testing molecules.

  2005cites this paper
• Quantifizierung von Kation‐π‐Wechselwirkungen in Protein‐Ligand‐Komplexen: Kristallstrukturanalyse eines Komplexes von Faktor Xa und einem quartären Ammonium‐Ion‐Liganden

  2005cites this paper
• Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.

  2005cites this paper
• Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.

  2005cites this paper
• Current trends in quantitative structure activity relationships on FXa inhibitors: Evaluation and comparative analysis

  2004cites this paper
• Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element.

  2004cites this paper
• The development of a novel native prothrombin assay for the more efficient management of oral anticoagulation therapy

  2004cites this paper
• Beta-strand mimetics.

  2004cites this paper
• Computational methods for the identification and optimisation of high quality leads.

  2004cites this paper
• Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa.

  2004cites this paper
• Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors.

  2004cites this paper
• Structure-based generation of viable leads from small combinatorial libraries.

  2004cites this paper
• Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.

  2004cites this paper
• Docking and scoring in virtual screening for drug discovery: methods and applications

  2004cites this paper
• Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.

  2003cites this paper
• Nouveaux derivés d'indole en tant qu'inhibiteurs du facteur xa

  2003cites this paper
• Improving structure-based virtual screening by multivariate analysis of scoring data.

  2003cites this paper
• Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket.

  2003cites this paper
• Single‐step perturbations to calculate free energy differences from unphysical reference states: Limits on size, flexibility, and character

  2003cites this paper
• Azaindole-Derivative als Faktor Xa Hemmer

  2003cites this paper
• Boosted leave-many-out cross-validation: the effect of training and test set diversity on PLS statistics

  2003cites this paper
• Comprehensive survey of combinatorial library synthesis: 2002.

  2003cites this paper
• Computer-aided drug discovery [version 1; peer review: 3 approved]

  year unknowncites this paper